We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Myogen to Become Gilead Subsidiary in $2.5 Billion Deal
Myogen to Become Gilead Subsidiary in $2.5 Billion Deal
October 2, 2006
Gilead Sciences is seeking to beef up its drug pipeline and its emphasis on treatments for pulmonary conditions, announcing Oct. 2 it will acquire Myogen for $2.5 billion.